secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apexigen, Inc. (—)
CIK:        0001814140
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024985
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 4.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apexigen reports positive Phase 2 data for sotigalimab in liposarcoma; mPFS 12.45 mo
--------------------------------------------------------------------------------

- Sotigalimab + doxorubicin achieved median PFS of 12.45 months in liposarcoma patients vs historical <5 months for doxorubicin alone.
- Apexigen plans to expand LPS cohort by 10 patients to inform potential Phase 3 registration-enabling trial.
- Favorable safety profile observed; data supports further development in first-line liposarcoma.
- Study is investigator-sponsored trial in collaboration with Columbia University (Gary Schwartz, PI).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/0000950170-22-024985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/apgn-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer